Allyx Therapeutics aims to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases

Altera Therapeutics is an early stage company developing a first-in-concept cell-penetrating antibody drug conjugates.

Cloverleaf Bio is developing a new platform of engineered tRNA therapeutics to improve patient outcomes in oncology.

D2B3 has a human monoclonal antibody that transiently and highly specifically opens the BBB, achieving high drug penetration to the brain.

ENSIGHT-AI is developing technologies that can identify structural heart disorders from widely available electrocardiograms (ECGs) and wearables

EpiTet Tx is using a small molecule-based approach to deplete epigenetically altered macrophages that perpetuate inflammation in chronic diseases.

Ferranyx is developing first in class small molecule ferroptosis inhibitors

FerRx Bio is developing an eye drop that uniquely targets the pathway central to the onset and progression of age-related macular degeneration (AMD) to prevent vision loss.

Maya + Yatra: Transformative Journey(Yatra) through Illusory (Maya) experiences

QwertyBio develops new types of biologics, coded from structure, to target hard-to-treat cancers.

RESA Therapeutics Is Designing Programmable MRNA To Enhance Tissue-specific Gene Targeting, Stability, And Protein Output.

Rho Bio is addressing vascular aging through reinvigoration of the lymphatic system with a novel protein therapy

Sarxion Biologics are developing engineering materials for regenerative medicine

St4te Therapeutics Is Developing Oral Small Molecule Therapies That Synergize With Nutrient-stimulated Hormones For The Treatment Of Obesity And Metabolic Diseases.

TargetSite Therapeutics is developing first-in-class therapeutics that inhibit enhancing miRNA-mRNA interactions.

Wavelet is devleoping non-invasive fetal brain monitoring using EEG, to reduce preventable brain injuries at birth, improving outcomes for mother and baby